Search
Displaying all 3 results
Linvoseltamab
go.drugbank.com/drugs/DB17447
ApprovedInvestigational
Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells. By binding to both targets simultaneously, linvoseltamab redirects T cells toward...
Relapsed Multiple Myeloma
go.drugbank.com/conditions/DBCOND0031510Drugs: Belantamab mafodotin · Carfilzomib · Ciltacabtagene autoleucel · Daratumumab · Dexamethasone · Elranatamab +8 moreRefractory Multiple Myeloma
go.drugbank.com/conditions/DBCOND0028542Drugs: Belantamab mafodotin · Carfilzomib · Carmustine · Ciltacabtagene autoleucel · Daratumumab · Dexamethasone +11 more